Epigenetics represents the impact of the combination of genetic, lifestyle and environmental factors on humans.
We utilise EpiSwitch™, a proprietary biomarker discovery platform licensed from our AIM listed shareholder Oxford Biodynamics Plc. Based on the latest advances in gene expression, non-coding RNA and epigenetics, EpiSwitch™ biomarkers are binary, stable and have both predictive and prognostic value.
EpiSwitch™ monitors a class of epigenetic biomarkers known as ‘chromosome conformation signatures’ (CCS), providing a compelling, stable framework from which changes in the regulation of a genome can be analysed, long before the results of these epigenetic changes manifest themselves as obvious abnormalities.
Oxford Biodynamics PLC (LON:OBD) was spun out from Oxford University in June 2007 with the aim of translating fundamental scientific advances into a commercialised platform technology and a new generation of biomarkers for cancer, ALS and other diseases.